Clinic Roundup
Ocular Therapeutix Inc., of Bedford, Mass., reported that a Phase II study of sustained-release travoprost (OTX-TP2) for glaucoma and ocular hypertension in 20 patients produced results comparable to topical brand name ophthalmic solutions travatan (Alcon Laboratories), Lumigan (Allergan Inc.) and Xalatan (Pfizer Inc.).
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.